| 3.9299 0.23 (6.21%) | 04-25 14:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.1 | 1-year : | 5.96 |
| Resists | First : | 4.36 | Second : | 5.1 |
| Pivot price | 3.81 |
|||
| Supports | First : | 3.39 | Second : | 2.79 |
| MAs | MA(5) : | 3.8 |
MA(20) : | 3.64 |
| MA(100) : | 3.16 |
MA(250) : | 5.79  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 50.9 |
D(3) : | 53.3 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 18 | Low : | 2.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVGR ] has closed below upper band by 35.8%. Bollinger Bands are 19.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.75 - 3.77 | 3.77 - 3.79 |
| Low: | 3.57 - 3.59 | 3.59 - 3.61 |
| Close: | 3.67 - 3.7 | 3.7 - 3.73 |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Wed, 03 Apr 2024
Avinger (AVGR) Announces 2.05M Share Offering by Selling Stockholders - StreetInsider.com
Thu, 21 Mar 2024
Avinger, Inc. (NASDAQ:AVGR) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 20 Mar 2024
Avinger: Q4 Earnings Snapshot - Quartz
Wed, 20 Mar 2024
AVGR Stock Earnings: Avinger Misses Revenue for Q4 2023 - InvestorPlace
Wed, 20 Mar 2024
Avinger, Inc. (AVGR) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 07 Mar 2024
Avinger Expands Market Reach and Secures $15M Funding - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 15.8 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 50 (K) |
| Shares Short P.Month | 23 (K) |
| EPS | -23.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.85 |
| Profit Margin | -239.5 % |
| Operating Margin | -242.2 % |
| Return on Assets (ttm) | -54.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -4.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.81 |
| EBITDA (p.s.) | -10.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | -0.82 |
| Price to Sales | 0.81 |
| Price to Cash Flow | -0.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|